Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator

The goal of this multicentre observational study is to compare the safety and effectiveness of rituximab biosimilars to the originator in Canadian patients with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), two main forms of ANCA-associated vasculitis (AAV).

The main questions it aims to answer are:

* Is there a difference in vasculitis control between originator and biosimilar rituximab?
* Is there a difference in adverse effects between originator and biosimilar rituximab?
* In the Canadian healthcare context, are wait times to receive approval (financial coverage) for rituximab shorter for biosimilars compared to originators?

Investigators will perform study assessments (including recording disease activity, damage, and adverse events) at the time of participants' usual clinical care visits, at regular intervals for 2 years after starting rituximab (for induction or maintenance treatment) or switching from an originator to a biosimilar as part of their usual care.

Researchers will compare outcomes among participants who have received rituximab originators (from 2018 onwards) or biosimilars as part of their usual care, to see if there are differences in relapses, remission rates, damage, serious infections, serious adverse events, and treatment approval wait times.

Background. Rituximab (RTX), a B-cell depleting therapy, has comparable efficacy to cyclophosphamide for induction of remission in severe granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) and superior efficacy to azathioprine for maintenance of remission (1,2). RTX is now a first-line therapy for remission induction and maintenance of remission in severe GPA and MPA (3).

Biosimilar RTX agents are molecules that are highly similar in structure to the 'originator' RTX that was initially studied and approved for the treatment of AAV. Among patients with rheumatoid arthritis, randomized controlled trials have demonstrated comparable efficacy and safety between originator and RTX biosimilars (4,5). Extension studies found that switching from originator to biosimilar does not alter disease activity, immunogenicity, or safety (6,7). Conversely, data on the outcomes of RTX biosimilars in AAV are limited. A retrospective study from Korea included 26 patients (\~80% MPA) who received either Truxima (n=15) or Mabthera/Rituxan (n=11) for second-line induction after failure or intolerance to cyclosphosphamide (CYC) (8). There were no obvious deviations in relapse, mortality, end-stage kidney disease, or cardiovascular outcomes compared to other studies with similar populations. A second study was a retrospective cohort study of 77 patients with GPA in India who received RTX biosimilars not available in Canada (Reditux, Rituxipca, Mabtas) for induction, maintenance, or both (9). Outcomes were comparable to those observed in randomized controlled trials of the originator drug.

Despite this scarce amount of data, many Canadian provincial and private funders are mandating the use of biosimilar agents (e.g. Truxima, Ruxience, Riximyo) for induction and maintenance of GPA and MPA, in place of the originator drug (Rituxan). There is a need for longitudinal prospective studies to determine comparative safety and effectiveness of RTX biosimilar agents in Canadian patients with GPA or MPA.

The COVID-19 pandemic has raised concerns for patients and providers about the safety of immunosuppression with RTX. Cohort studies of patients with rheumatic disease have reported an association between RTX and the risk of severe COVID-19 and death from COVID-19 (10-12). Rituximab may also reduce the immunogenicity, and thus the effectiveness, of COVID-19 vaccination, as has been observed for other vaccines (13).

Objectives. The overarching objective of this study is to compare the real-world safety and effectiveness of originator and biosimilar RTX for the treatment of GPA/MPA.

Specific objectives:

To determine, in patients with GPA/MPA receiving biosimilar or originator RTX for remission induction and/or maintenance:

1. Frequency of clinical remission at 6 and 24 months
2. Frequency and time to relapse and major relapse at 6 and 24 months
3. Frequency and time to serious adverse events (SAEs) at 6 and 24 months
4. Frequency and time to serious infection (SI) at 6 and 24 months
5. Frequency and time to discontinuation of RTX due to adverse events or relapse
6. Disease damage at 6 and 24 months
7. Wait time from RTX application to approval and first infusion
8. Frequency of COVID-19 infections and hospitalizations

Participant recruitment:

Potential prospective participants meeting inclusion criteria will be identified by clinicians providing care to patients with GPA or MPA (i.e., the local study investigators) when patients attend their routine clinical care visits (in-person or telemedicine). The local study investigators (i.e. the clinician providing care to the patient) will then describe the study to potential participants, and if interested, will be given the informed consent form to read (in paper or electronic format, per the potential participant's wishes). The potential participant will have the opportunity to ask any questions to the clinician/investigator or research coordinator, who will be the person obtaining consent. The potential participant will also have the option of reading the consent form at a later date, and will be given the contact information of the study coordinator should he/she wish to notify the investigator and/or coordinator of his/her intent to participate at a later date.

Informed consent Informed consent will be obtained either electronically (via the secure REDCap platform) or using paper consent forms during usual care visits. Patients' participation is entirely voluntary. Prospective participants will provide informed consent to participate in the study and may discontinue their participation at any time.

This study will be conducted in accord with the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (2018), as well as in respect of the requirements set out in the applicable standard operation procedures of the Research Institute of the McGill University Health Centre Research Institute and of the McGill University Health Centre Research Ethics Board. The McGill University Health Centre Research Ethics Board has reviewed this study and is responsible for monitoring it at all participating institutions in the health and social services network in Québec. Each participating center outside the Réseau de la Santé et des Services Sociaux has approval from their local Research Ethics Board.

Data Collection

Participants will be followed for 24 months.

The following will be collected at enrolment/baseline:

* Age, sex, race/ethnicity, province, education, diagnosis (GPA or MPA), date of diagnosis, ANCA status at diagnosis, number of prior relapses
* Organ involvement at last relapse or at diagnosis
* Birmingham Vasculitis Activity Score (v3, BVAS) and Vasculitis Damage Index (VDI) at time of RTX treatment
* Prior RTX and cyclophosphamide doses received in the last 5 years, dates
* Type of RTX product received
* Payor (i.e., government drug plan or private insurance or participant out-of-pocket, assessed based on clinical records of drug applications and approvals located in the chart and/or participant report)
* Date of most recent RTX application and date of first infusion
* Current therapies
* Glucocorticoids with current dose
* Other immunosuppressants
* Pneumocystis/infection prophylaxis
* If switching from RTX originator to biosimilar (or vice versa), reason for switch
* COVID-19 infection and vaccination with dates if applicable

Subsequent study assessments Data collection/study visits will occur at Months 3 (+/-1) (RTX induction recipients only) , 6(+/-3), 12(+/-3), and 24(+/-6), coinciding with usual practice clinical care visits.

At these visits, the following information will be recorded, based on physician clinical assessments (participant history, physical exam), and medical chart reviews (outcome definitions are described in Outcomes):

* Interval RTX infusions: doses, dates, RTX product, payor (based on clinical records of drug applications and approvals and/or participant report)
* If RTX infusions were stopped/delayed, reason and date
* Current (ongoing) therapies
* Current GC dose
* Other immunosuppressants
* pneumocystis/infection prophylaxis
* BVAS
* VDI
* Interval disease relapses with date
* Interval serious infections (SIs) with date
* Interval Serious Adverse Events (SAEs) with date
* Symptomatic late onset neutropenia with date
* Symptomatic hypogammaglobulinemia with date
* Interval COVID-19 infection and vaccination with dates
* Date of death and cause of death if applicable

Data will be collected and entered into secure electronic data capture (REDCap) and/or through paper Case Report Forms (for centers without access to REDCap), and subsequently entered centrally in the main study REDCap database.

As this study will be conducted during the COVID-19 pandemic, virtual visits instead of in-person visits will be accepted as they represent the frequent usual care at the time of this pandemic.

Study size rational:

Planned enrollment will be 120 RTX biosimilar users and 120 RTX originator users, either prospectively or from existing registries with retrospective collection, over the course of 18 months, across 8 different participating centres. This study size would provide 80% power (at a significance level of 0.05) to show a 2-fold increase in the percentage with relapses in the biosimilar group, assuming 15% have a relapse at 24 months in the originator group.

Significance Currently very limited data exist on comparative safety or effectiveness of RTX biosimilars versus the originator drug in ANCA-associated vasculitis. This study will provide real-world data on patients receiving either RTX originator or biosimilar for induction or maintenance of GPA or MPA to permit these comparisons.

Funding The study is funded by the Canadian Network for Advanced Interdisciplinary Methods for comparative effectiveness research (CAN-AIM). CAN-AIM has a mandate to compare safety and effectiveness of originator and biosimilar drugs across diseases and disciplines. The study is also funded by the Canadian Initiative for Outcomes in Rheumatology cAre (CIORA), which ultimately aims to improve the care of Canadians diagnosed with a rheumatic disease.

Eligibility Criteria:
Inclusion Criteria:

Prospective cohort:

Initiated within the last 6 months:

1. RTX biosimilar or originator for induction OR
2. RTX biosimilar or originator for maintenance (with or without prior RTX induction) OR
3. Switched from RTX originator maintenance to biosimilar maintenance (4-12 months between infusions)

Historical cohort:

Followed in a prospective longitudinal cohort study/registry within the CanVasc network, and initiated the following after January 1, 2018 but \>6 months prior to study enrollment

1. RTX biosimilar or originator for induction OR
2. RTX biosimilar or originator for maintenance (with or without RTX induction)

Exclusion Criteria:

* patients without a diagnosis of GPA or MPA
* patients who did not/are not receiving RTX induction or maintenance therapy
* patients who initiated most recent RTX treatment course prior to Jan 1, 2018
* patients receiving RTX for reasons other than GPA or MPA induction or maintenance (e.g. other concurrent disease)
* unable to provide informed consent